Sign up here to receive news updates via email.
-
October 30, 2017 |
Media, Press Releases
BERG Enters Into an Agreement With Sanofi Pasteur to Identify Biomarkers of Flu Vaccine Performance
read moreMolecular Data Will be Analyzed Using Artificial Intelligence Through BERG’s Interrogative Biology® Platform to Better Understand Influenza Vaccination Response BOSTON — BERG, a biopharmaceutical company that merges biology with technology, today announced a new research effort with Sanofi Pasteur, the influenza vaccine global leader. Under this agreement, BERG will generate and model data using BERG’s…
-
October 27, 2017 |
Media, Press Releases
BERG Honored with Partner in Progress Award from DEBRA of America at Annual Benefit for Rare Disease Epidermolysis Bullosa
read moreBERG’s BPM 31510 Drug Candidate Recognized as Potential Novel Therapy for Treating Rare Disease BOSTON — BERG, a biopharmaceutical company that merges biology with technology, today announced that the Company was honored with a Partners in Progress Award from the Dystrophic Epidermolysis Bullosa Research Association of America (debra of America). The award recognizes the Company’s…
-
October 3, 2017 |
Media, Press Releases
BERG Broadens Relationship with Department Of Defense (DoD) Center For Prostate Disease Research with New Predictive Biomarker Test for Prostate Cancer
read moreNew Clinical Evidence Guided by Artificial Intelligence that Could Significantly Enhance Prostate Cancer Detection and Reduce Over-Diagnosis and Unnecessary Treatments in Benign Prostate Hyperplasia Patients arises from Research Collaboration with BERG and the Center for Prostate Disease (CPDR) in the Department of Surgery, Uniformed Services University (USU) BOSTON — BERG, a biopharmaceutical company that merges…
-
September 11, 2017 |
Media, Press Releases
BERG Presents Key Clinical Data at ESMO 2017 on BPM 31510 for Advanced Pancreatic Cancer Patients and BPM 31543 for Preventing Hair-Loss in Patients Treated With Chemotherapy
read moreNew Data Show Promising Results and Support Continued Clinical Development,Highlights Success of Interrogative Biology Platform to Advance Potential New Treatment Options for Cancer Patients BOSTON, Sept. 11, 2017 — BERG, a biopharmaceutical company that merges biology with technology to map the nature of diseases, today announced two poster presentations showing promising clinical data that were unveiled…
-
August 28, 2017 |
Media, Press Releases
BERG Forms Research Collaboration with AstraZeneca to Identify New Therapeutic Targets to Treat Neurological Disorders such as Parkinson’s Disease
read moreCollaboration to Focus on a Disease Target in Parkinson’s Disease With Berg’s Interrogative Biology® Technology BOSTON, Aug. 28, 2017 – BERG, a biopharmaceutical company that merges biology with technology to map the nature of diseases, today announced a research collaboration with AstraZeneca to identify and evaluate novel targets and therapeutics to treat neurological disorders such…
-
May 15, 2017 |
Media, Press Releases
BERG Announces New Partnership with debra of America to Tackle Epidermolysis Bullosa, a Rare Genetic Tissue Disorder
read moreBiopharmaceutical and Patient Advocacy Group Join Forces to Galvanize the Disease Community and Advance Treatment Research BOSTON, May 15, 2017 — BERG, a biopharmaceutical company uncovering health solutions through a data-driven, biological research approach, today announced they have entered into a partnership agreement with The Dystrophic Epidermolysis Bullosa Research Association of America (debra of America)…
